Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vosteon
- Development stage
- Unknown
- Lead developer
- MEPROFARM
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vosteon is an oral combination dietary supplement developed and marketed by Meprofarm in Indonesia. It is formulated to support joint and bone health, particularly for individuals suffering from osteoarthritis, joint stiffness, or age-related joint degeneration. The supplement contains four active ingredients: glucosamine hydrochloride and chondroitin sulfate, which work synergistically to promote cartilage repair and maintain joint lubrication; ipriflavone, a synthetic isoflavone derivative that inhibits bone resorption and supports bone density; and calcium citrate, which provides an easily absorbable source of calcium to maintain bone strength.
- Brand names
- Vosteon
02
Targets
ESR1 (ERα)ESR2 (ERβ)
Beyond the preview
Go deeper on Vosteon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vosteon.